View the poster here.
Dimerix Presents Detailed Subgroup Analysis from DMX-200 Phase 2a trial in Chronic Kidney Disease Showing Compelling Efficacy Signals in Diabetic Nephropathy Patients
- Detailed data from Dimerix’s DMX-200 Phase 2a trial in Chronic Kidney Disease (CKD) presented at American Society of Nephrology’s (ASN) Annual Kidney Week conference in New Orleans this week
- Post hoc, detailed data […]
Baker Young Stockbrokers have initiated coverage of Dimerix Limited.
The research report is available here:
Dimerix receives ethics committee approval for pharmacokinetic trial of new extended release formulation
Dimerix Limited (ASX: DXB), is pleased to announce that it has received ethics committee approval for a study in healthy volunteers to determine the pharmacokinetic properties of the novel extended release propagermanium tablet to be used in the Company’s DMX-200 Phase 2b trial in Chronic Kidney Disease.
Read the full release […]
We are very pleased to announce the appointment of a Medical Advisory Board (MAB) to help guide the Company’s DMX-200 clinical program.
The Medical Advisory Board will provide clinical and strategic input into the Company’s lead program, DMX-200 in Chronic Kidney Disease and will provide guidance to the Company as it shapes and progresses its DMX-200 […]
Dimerix (ASX:DXB) is pleased to announce the receipt of a Research and Development (R&D) Tax Incentive refund of $545,771 for the 2016/2017 financial year.
The refund relates to eligible expenditure on the company’s lead program, DMX-200, which has just completed a successful Phase 2a trial, meeting its primary endpoint (safety and tolerability) and showing signals of […]